Effects of estrogen replacement therapy on thrombin generation

Area of Science:

• Endocrinology
• Hematology
• Reproductive Medicine

Background:

• Menopause is associated with hormonal changes affecting hemostasis.
• Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
• The impact of different HRT formulations on blood clotting requires investigation.

Purpose of the Study:

• To investigate the hemostatic system in menopausal women.
• To evaluate the effects of transdermal estradiol (TTS 50) and conjugated equine estrogen (CEE) on blood clotting parameters.
• To determine the relationship between estradiol levels and clotting activation.

Main Methods:

• Study included 13 women on TTS 50 and 9 on CEE.
• Evaluated markers of coagulation and fibrinolysis, including fibrinopeptide A (FPA), thrombin-antithrombin (TAT) complexes, and protein C.
• Measurements were taken before and after three months of treatment.

Main Results:

• Fibrinopeptide A (FPA) levels significantly increased with TTS 50 treatment (p < 0.001).
• Protein C levels significantly decreased with both TTS 50 (p < 0.001) and CEE (p < 0.05).
• No significant changes were observed in TAT complexes, antithrombin (AT), platelet function, or fibrinolytic activity.

Conclusions:

• Unopposed transdermal estradiol induces mild but significant blood clotting activation.
• This activation is directly related to estradiol levels and its biological activity.
• Transdermal estradiol therapy may influence thrombotic risk in menopausal women.